

# RNA biology I

Genomics Bio5488

Guoyan Zhao

Associate Professor of Genetics & Neurology



# Class Information

---



- Lectures: Mon, Wed 10:00-11:30 am
  - February 16: RNA biology I
  - February 18: RNA biology II
- Lab: February 20, 2026, Fri 10:00-11:30 am (Bring your laptop)
  - Yuchen (Alana) Cheng, [c.yuchenalana@wustl.edu](mailto:c.yuchenalana@wustl.edu)
  - Benjamin Van Court, [b.vancourt@wustl.edu](mailto:b.vancourt@wustl.edu)
- Questions, suggestions and feedbacks: [gzhao@wustl.edu](mailto:gzhao@wustl.edu)




# RNA biology

---

- RNA biology I
  - Introduction of RNA type and function
  - RNA quantification technology
    - Targeted
      - Northern blotting
      - RT-qPCR
      - *In situ* Hybridization
      - Reporter Assay
    - High-throughput
      - Microarray
      - RNA-seq
  - Experimental design principles
  - General workflow for RNA quantification
- RNA biology II
  - Transcriptome profiling by RNA-seq
    - Experimental design
    - RNA quantification
    - Quality control and normalization
    - Outlier detection
    - Differentially expressed gene detection
    - Result interpretation
- RNA biology Lab
  - RNA-seq data analysis

Goals: RNA biology, quantification, important concepts and considerations in experimental design and data analysis


# Central Dogma






# Transcription

## Initiation



## Elongation




transcription  
bubble



# Transcription Initiation

## Formation of the initiation complex




RNA polymerase II is responsible for the synthesis of mRNA from protein-coding genes.

Two types of transcription factors:

- General transcription factors (basic transcription machinery): transcription from all polymerase II promoters
- Regulatory transcription factors




# RNA types

## Coding RNA



## Non-coding RNA

### Infrastructural ncRNAs





### Regulatory ncRNAs

siRNA



miRNA




- small PIWI-interacting RNAs (piRNAs):
- promoter-associated RNAs (PARs)
- enhancer RNAs (eRNAs)



# Coding RNA - mRNA

## life cycle of an mRNA




## mRNA modification

- **in the coding sequence**
  - alter translation fidelity
  - decoding
  - ribosome transit speeds and accuracy, often leading to pausing or stalling.
- **in the untranslated regions**
  - stability of the RNA structure
  - ability to form RNA–protein interactions
  - impact mRNA maturation, translation, and decay




# Non-coding RNAs (ncRNAs) - infrastructural ncRNAs

Non-coding RNAs (ncRNAs) are a heterogeneous group of transcripts that, by definition, are not translated into proteins



- **Ribosomal RNA (rRNA):**
  - 1) structural elements in the assembly of ribosomes
  - 2) transcribed from ribosomal DNA (rDNA). The rDNA sequence is arranged as tandem repeat units in the genome.
  - 3) the most abundant form of RNA found in most cells (about 80% of cellular RNA).




- **Transfer RNA (tRNA):**

Robert W. Holley won the 1968 Nobel Prize in Physiology or Medicine for describing the structure and determining the nucleotide sequence of alanine transfer RNA, linking DNA and protein synthesis.






# Non-coding RNAs (ncRNAs) - infrastructural ncRNAs cont.



- **Small nuclear RNAs (snRNAs):**
- critical components of the spliceosome that catalyze the splicing of pre-mRNA.



- **Small nucleolar RNAs (snoRNAs):**
- widely present in the nucleoli of eukaryotic cells
- important for RNA biogenesis and chemical modifications of rRNA, tRNA, and mRNA.


# Non-coding RNAs (ncRNAs) – Regulatory ncRNAs





- small interfering RNAs (siRNAs):
- ~ 20 base pairs
- induces gene silencing by targeting complementary mRNA for degradation



Andrew Z. Fire and Craig C. Mello (2006)  
siRNAs and RNA interference (RNAi)




- microRNAs (miRNAs):
- ~22 nucleotides
- leads to mRNA degradation or inhibition of mRNA translation



Victor Ambros and Gary Ruvkun (2024)  
miRNA and post-transcriptional gene regulation




# Mechanism comparison between siRNAs and miRNA



RISC:  
RNA-induced silencing complex

# Non-coding RNAs (ncRNAs) – Regulatory ncRNAs cont.

Comparison of three RNA-silencing pathways  
that all depend on the Argonaute family proteins



- small PIWI-interacting RNAs (piRNAs):
- 21/24/26–31 nucleotides
- piRISC: piRNA-induce silencing complex
- protect genome integrity

single- vs. double- stranded RNA precursors

Binding proteins: PIWI vs. AGO proteins

3'-end modification: 2'-O-methyl vs. 2',3' hydroxy

Different target genes:


- miRNAs: endogenous genes
- siRNA: exogenous genes
- piRNAs: transposon silencing



# Non-coding RNAs (ncRNAs) – Regulatory ncRNAs cont.

- Long non-coding RNAs (lncRNAs):
  - non-coding transcripts of more than 200 nucleotides

- linear lncRNAs:



1. Most linear lncRNAs are transcribed by RNA polymerase II
2. Presumably are capped, polyadenylated, and contain exon-exon splice junctions like mRNAs
3. Based on their genomic locations relative to adjacent protein-coding genes, lncRNAs are classified as sense, antisense, bidirectional, intronic, and intergenic lncRNAs. They are also derived from 'pseudogenes',
4. Regulate many aspects of cell differentiation, development and other physiological processes.



- circular RNAs (circRNAs):

- generated by back-splicing of linear transcripts during the mRNAs splicing
- can be derived from exons, introns, exon–intron junctions or intergenic regions of the genome.
- tissue- and cell-specific expression patterns, abundant
- more resistant to degradation, have a longer half-life than mRNAs and linear lncRNAs
- carry out diverse regulatory functions


# Different Classes of Genes are Transcribed by Different Eukaryotic RNA Polymerases



Type of RNA synthesized	RNA polymerase	
mRNA	II	
tRNA	III	
rRNA	5.8S, 18S, 28S	
	5S	
Some small RNA	e.g. snRNA	II or III
Mitochondrial genes	Mitochondrial RNA polymerases	
Chloroplast genes	Chloroplast RNA polymerases	



# RNA in Therapeutics



Katalin Karikó and Drew Weissman was awarded the 2023 Nobel Prize for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19.



# Why Do We Care About Gene Expression?

---



- Gene expression profiles provide a snapshot of cellular/ tissue state at the molecular scale
- Gene expression profiles provide a snapshot of cumulative interactions of many regulatory relationships
- Gene expression is a ‘proxy’ measure for transcription/ translation/ functional events

# What can we learn by measuring gene expression?

---



- Cell function and behavior
- Developmental biology
- Environmental impacts
- Disease mechanisms
- Personalized medicine

# The assumptions behind the conclusions


---



- Assume that gene expression levels correspond to functional protein levels
- Assume that a normal cell has a standard expression profile/ signature
- Assume that changes in expression profile indicate that some property or functional changes



# How Much of the Genome is Transcribed?



## Estimates from ENCODE

The ENCODE (ENCyclopedia Of DNA Elements) Project Consortium. Science. 2004

- Recent high-throughput transcriptomic analyses have revealed that eukaryotic genomes transcribe up to 90 % of the genomic DNA.
- mRNA: Only 1–2% of these transcripts encode for proteins
- the vast majority are transcribed as non-coding RNAs (ncRNAs).

# Does mRNA Level == Protein Level?


---



- Yeast: significant discrepancy between mRNA and protein levels
  - 156 genes in yeast (Gygi et al., 1999 Mol Cell Biol)
  - 245 genes in yeast on galactose/ ethanol medium (Griffen et al., 2002 Mol Cell Proteomics)
- mammalian cells: significant discrepancy between mRNA and protein levels
  - The mean correlations were ~0.25. Only 1/3 had significant correlations ( $> 0.445$ ) between protein and RNA levels. (Gry et al., BMC Genomics, 2009)
  - 55 target proteins (Edfors et al., Mol Syst Biol. 2016)
  - ~30–40% of the variance in protein abundance is explained by mRNA abundance (Vogel & Marcotte, Nature Reviews Genetics, 2012)
- Differentially expressed mRNAs correlate significantly better with their protein product than non-differentially expressed mRNAs. (Koussounadis et al. Scientific , 2015)

# Regulation of protein abundance

Genome




- Copy number variation
- Promoters, enhancers, silencers, insulators
- histone and DNA modifications
- 3D genome structures

the loci controlling RNA expression (eQTLs) had only a 50% overlap with the loci controlling protein expression (pQTLs)

- mRNA stability, modification
- miRNAs
- siRNA
- piRNA
- lncRNA

abundance of a transcript ≠ the use of a transcript

Protein abundance






# RNA quantification method

---

- Targeted
  1. Northern blotting
  2. *In situ* Hybridization
  3. Reverse transcription quantitative PCR (RT-qPCR)
  4. Reporter Assay
- High-throughput
  1. Microarray
  2. RNA-seq
  3. Single cell/nucleus RNA-seq




# Measuring Gene Expression: 1. Northern blot



- To determine the size and quantity of specific RNA molecules among a mixture of RNA.

Testes-determining factor



complementary to target RNA sequence  
single strand  
labeled with radioactive isotope or fluorescent dye



# Northern blot pros & cons

## Advantages

- the simplicity of the procedure and low cost
- Very sensitive due to use of radioactive probes
- Nearly infinite dynamic range

## Disadvantages


- time-consuming
- only a small number of samples can be analyzed at one time
- requires a large amount of starting material
- Quality control (non-specific hybridization)

# Measuring Gene Expression: 2. *In situ* Hybridization




- To localize and detect DNA or RNA sequences in morphologically preserved cells, tissue sections, and even whole tissue. (*in situ* = in the original place)

Probe labeling	Visualization
radio-labeled bases	autoradiography
fluorescent-labeled bases	fluorescence microscopy
antigen-labeled bases	immunohistochemistry



zebrafish  
lyve1



# *In situ* Hybridization pros & cons



## Advantages

- provide spatial information of cellular content
- Single-cell sensitivity
- Spatial and temporal analysis
- Can be used on archival tissues

## Disadvantages

- Expensive
- Time consuming
- require experienced personnel
- probe- and sample-specific, have to be optimized for each set of conditions empirically.



# Measuring Gene Expression: 3. RT-qPCR




## Reverse transcription quantitative PCR (RT-qPCR)

- the gold standard for accurate, sensitive and fast method of nucleic acid detection and quantification
- relies on fluorescence to detect and quantify nucleic acid amplification products
- broad applications

1. Convert total RNA to cDNA
2. Add cDNA to RT-qPCR master mix and aliquot mixture across PCR array





3. Run in your RT-qPCR instrument




# Good vs. bad RT-qPCR design




Phases of the PCR amplification curve



well-designed experiment



poorly-designed experiment





# RT-qPCR pros & cons



## Advantages

- Highly sensitive, quantitative and reproducible
- ‘Gold-standard’
- Excellent dynamic range
- Fast results



## Disadvantages

- Expensive
- Not high-throughput
- Non-specific amplification can lead to false positives
- Always have controls – positive and negative controls

# Measuring Gene Expression: 4. Reporter Gene Assay




$$\text{Promoter activity} = \text{Luciferase activity} / \text{Cell number or cellular enzyme activity}$$



$$\text{Promoter activity} = \text{Firefly luciferase activity} / \text{Renilla luciferase activity}$$

## In vivo bioluminescence imaging





# Application of Reporter Gene Assay

---

- Application:
  - Determine promoter or enhance strength
  - Interactions between promoters and transcription factors
  - Protein-protein interactions
  - Protein trafficking
  - Signal transduction
  - Drug screening both in vitro and in vivo
- Commonly used reporter genes:
  - luciferases, green fluorescent protein (GFP),  $\beta$ -galactosidase, chloramphenicol acetyltransferase,  $\beta$ -glucuronidase

# Reporter Assay pos & cons

---



## Advantages


- *In vivo* applications
- Highly sensitive
- New technology enables longitudinal studies

## Disadvantages

- Stability issues
- Not high-throughput
- Quantification *in vivo* is affected by many variables



# High-throughput technology: 1. Microarray



- Principle: hybridization between two DNA strands
- Quantifies RNA through template hybridization and dye intensity



# Microarray pros & cons

## Advantages

- High-throughput
- Reliable and more cost effective than RNA-Seq for gene expression profiling in model organisms
- Kit systems (easy/ accessible)


## Disadvantages

- Need target transcripts information
- Quality and quality control highly variable
- Cross-hybridization
- Multiple tissue samples cannot be tested in one assay; a control and a test tissue sample need to be prepared separately



# High-throughput technology: 2. RNA-seq

- RNA sequencing (RNA-seq) is a genomic technique that uses next-generation sequencing to analyze the quantity and presence of RNA molecules in a biological sample.



# RNA-seq pros & cons



## Advantages

- Transcript identification and quantification in a single assay
- Very direct and quantitative
- No prior knowledge of genome required
- A greater dynamic range to quantify transcripts allows more differentially expressed gene detection
- single-nucleotide resolution allows the detection of genetic variants, transcript isoforms and splice variants

## Disadvantages

- Amplification steps can offset balance between high/ low abundance transcripts
- High cost than microarray
- Analysis is non-trivial – no optimal pipeline for the variety of different applications and analysis scenarios



# Experimental Design and General Workflow

“Seventy percent of whether your experiment will work is determined before you touch the first test tube” - Sun, *Nature Reviews Mol Cell Biol* (2004)

How much risk can I afford to take?



How much can I trust various components in an experiment?



How thoroughly should I plan my experiment?




Carrying out the experiment



# Maximizing experimental success

- To pay attention to even minute details, to the point that you become a perfectionist, will save you invaluable time in the long run.
- ***Thorough planning and understanding of the protocol.***
  - write a step-by-step flowchart that details the entire procedure from the beginning to the end thoroughly understand every step
  - compare the flowchart you generate with the protocols from several sources to see whether they are consistent.
  - check your detailed design of a particularly crucial or time-consuming experiment with your mentor or experienced colleague
- ***Importance of positive and negative controls***
- ***A well-kept notebook.***
  - date, the hypotheses and/or questions, key protocols (in the form of flowcharts), reagents, etc.



# Gene Expression Experimental Design

---



Which technology should I use? – what's your research question?

- **Northern blotting:**
  - Best for determining the size of a specific RNA transcript.
- **RT-PCR:**
  - The most sensitive method for detecting and quantification of gene expression
  - Ideal for analyzing a few genes with high accuracy
- **In situ hybridization:**
  - visualize the location of a specific RNA within a tissue or cell, spatial information
- **Reporter Assay:**
  - Used to study the regulatory elements of a gene by monitoring the activity of a reporter gene under different conditions.
- **Microarray:**
  - Allows for simultaneous analysis of thousands of genes, useful for exploring global gene expression patterns of model organisms.
- **RNA-seq:**
  - Provides a comprehensive view of the transcriptome, including novel transcripts and isoforms, offering the most detailed information about gene expression

# Comparison of gene expression between conditions

---



Hypothesis Statement:

Formulate your research question into two competing hypotheses:

Case Study: Detecting disease-associated APOE expression changes in Alzheimer's disease (AD) brain tissues.

Scientific Question: Do APOE expression differ between brains from individuals with AD and cognitively normal controls?

Null hypothesis ( $H_0$ ): Mean expression of APOE is the same in AD and control brains

$$\mu_{AD} = \mu_{Control}$$


Alternative hypothesis ( $H_a$ ): APOE expression differs (or is higher) in AD

two-tailed test:  $\mu_{AD} \neq \mu_{Control}$

one-tailed test:  $\mu_{AD} > \mu_{Control}$



# Hypothesis Testing



$H_0$ : Mean expression of APOE is the same in AD and control brains:  $\mu_{AD} = \mu_{Control}$

$H_a$ : APOE expression differs (or is higher) in AD:  $\mu_{AD} \neq \mu_{Control}$

It is important to set  $\alpha$  before the experiment (a priori). typical value of  $\alpha = 0.05$

Ensure the data is representative of the population.

Selecting an appropriate sampling method.

Determining the sample size (power calculation).

Data type (continuous, categorical, etc.), Distribution of the data (normal, non-normal), Sample size, Number of groups being compared: t-tests, chi-square tests, ANOVA

quantifies how much the sample data deviates from the null hypothesis.

p-value: probability of observing results as extreme as the sample data, assuming the null hypothesis is true.

If  $p\text{-value} \leq \alpha$ :

Reject the null hypothesis, evidence supports the alternative hypothesis.

If  $p\text{-value} > \alpha$ :

Fail to reject the null hypothesis, insufficient evidence to support the alternative hypothesis.




# Errors in Decision Making

Conclusion based on data	Null Hypothesis ( $H_0$ ) is True	Null Hypothesis ( $H_0$ ) is False
Reject Null Hypothesis	Type-I Error ( $\alpha$ ) Common values: 0.05	Correct conclusion (Power = $1-\beta$ ) Common values: 0.8
Fail to Reject Null Hypothesis	Confidence interval ( $1-\alpha$ ) Common values: 0.95	Type II Error ( $\beta$ )

- Alpha: The maximum probability of making Type I error.  $\alpha = 0.05$
- Beta: When the alternative hypothesis is true, the probability of rejecting it (the probability of making a type II error)
- Power: The ability of the test to detect a true effect when it's there



# Power and sample size



- Increase sample size leads to increase of power
- diminishing returns for adding more and more subjects



# Choosing an Effect Size

$$d = \frac{\bar{x}_1 - \bar{x}_2}{s}$$

Cohen's  $d$  = the difference between two means divided by the pooled standard deviation

Effect Size	$d$
Very Small	0.01
Small	0.2
Medium	0.5
Large	0.8
Very Large	1.2
Huge	2.0




# Common Effect Size Indices

Index	Description <sup>b</sup>	Effect Size	Comments
Between groups			
Cohen's $d^a$	$d = M_1 - M_2 / s$ $M_1 - M_2$ is the difference between the group means ( $M$ ); $s$ is the standard deviation of either group	Small 0.2 Medium 0.5 Large 0.8 Very large 1.3	Can be used at planning stage to find the sample size required for sufficient power for your study
Odds ratio (OR)	Group 1 odds of outcome Group 2 odds of outcome  If OR = 1, the odds of outcome are equally likely in both groups	Small 1.5 Medium 2 Large 3	For binary outcome variables  Compares odds of outcome occurring from one intervention vs another
Measures of association			
Pearson's $r$ correlation	Range, $-1$ to $1$	Small $\pm 0.2$ Medium $\pm 0.5$ Large $\pm 0.8$	Measures the degree of linear relationship between two quantitative variables

# Power Analysis



- Four inter-related concepts:
  - power
  - effect size
  - sample size
  - significance level ( $\alpha$ )
- Each is a function of the other three. If three of these values are fixed, the fourth is completely determined (Cohen, 1988)



## Software


- G\*Power 3: Faul et al., Behavior Research Methods, 2007
- Power Analysis & Sample Size (PASS)
- R: pwr package



# Why and when do we need power analysis?

- To determine the necessary number of subjects needed to detect an effect of a given size.
- To determine power, given an effect size and the number of subjects available.
- No point to conducting a study that is seriously underpowered.

Power analysis is conducted before the study begins.



The Journal of Rheumatology 2022;xx:xxxx  
doi:10.3899/jrheum.21115  
First Release May 15 2022

Expert Review

Post Hoc Power Calculations: An Inappropriate Method for Interpreting the Findings of a Research Study

Michael G. Heckman<sup>1</sup> , John M. Davis III<sup>2</sup> , and Cynthia S. Crowson<sup>3</sup>



**Post-hoc** power estimates (power calculated for hypothesis tests after performing them) are sometimes requested by reviewers in an attempt to promote more rigorous designs. However, they should never be requested or reported because they have been shown to be logically invalid and practically misleading. We review the problems associated with **post-hoc** power, particularly the fact that the resulting calculated power is a monotone function of the *p*-value and therefore contains no additional helpful information. We then discuss some

The Interpretation of Statistical Power after the Data have been Gathered, Dziak et al., Curr Psychol. 2018

**Power analysis is only meaningful for future experimental design.**



# A priori vs. Post-Hoc power analysis

---

- Power analysis is essential before data collection:
  - Determine required sample size ( $n$ ) for detecting a biologically meaningful effect
  - Avoid underpowered studies (false negatives)
  - Prevent overpowered studies (wasted resources, inflated trivial significance)
- A design-stage (a priori) power analysis is the gold standard use.
- Use of power for completed studies (Post-Hoc Power analysis)
  - Interpreting negative results: no true effect vs. lacked power to detect a realistic effect size
  - A high-profile claim from an under-powered study should be viewed with extreme skepticism.

**Smallest Effect Size of Interest (SESOI):** An effect size that is biologically or clinically meaningful, not just statistically significant.

# General Workflow: Multiple Testing Problem

---



- Measure the expression of thousands of genes at a time
  - For each gene we test the null hypothesis that there is no differential expression.
  - Many thousands of statistical tests are performed
- Suppose  $g$  null hypotheses are being tested
  - $g^*\alpha$  = The expected number of false positives if ALL null hypotheses were true.
  - $10,000 \times 0.05 = 500$  false positive DEGs
- Family-wise error rate (FWER): the probability of rejecting at least one null hypothesis given they are all true (1 false positive): Bonferroni Correction:  $\frac{\alpha}{g}$
- False Discovery Rate:  $p(k) \leq (k / g) * \alpha$

# Gene Expression General Workflow

---




- Sample acquisition and handling
- RNA extraction
- RNA concentration and quality assessment
- Assay optimization and data collection
- Data analysis

# General Workflow: Sample acquisition and handling




- Type of replicates:
  - Biological replicates
  - Technical replicates
- As many Biological replicates as possible





# General Workflow: RNA Extraction

- RNA extracted from tissue is very heterogeneous
  - Many cells and difference cell types
- Total RNA contains different types of RNA
  - Only 1-2% is mRNA
  - Remainder is rRNA, tRNA, etc
- extremely susceptible to degradation





# General Workflow: RNA Quality Control

---

It is important to ensure you have an intact RNA preparation, at the correct concentration and purity, before jumping into your experiments.

## 1. Measuring RNA concentration

- Measure UV absorption of the sample using a spectrophotometer at 260nm
- the Beer Lambert Law: an A<sub>260</sub> of 1.0 = 40 µg/mL of RNA.



## 2. Measuring RNA Purity

- Protein Contamination: A<sub>260</sub>/A<sub>280</sub> ratio
  - Pure RNA A<sub>260</sub>/A<sub>280</sub> = 2.1
  - Values between 1.8–2.0 are considered acceptable for many protocols.
- Other contaminants: A<sub>230</sub>
  - A high peak at A<sub>230</sub> indicates contamination with guanidine salts or phenol.
  - The ideal A<sub>260</sub>/A<sub>230</sub> ratio is greater than 1.5




# Measuring RNA Integrity

- Agarose Gel



- Bioanalyzers






- more expensive
- use small amounts of RNA (1–2 $\mu$ L) and microfluidics
- determine the quantity and quality of RNA samples.
- RNA Integrity Number (RIN)





# General Workflow: Assay Optimization and Data Collection

- Assay-specific





# General Workflow: Data Analysis

---

- Reference sample, genome, gene,
  - Controls could be heterogenous
  - Reference genome versions
  - Reference gene expression could change in treatment group (GAPDH, ACTB)
- Data normalization
  - Different loading quantity
  - Different input number of cells
  - Different transfection efficiency
- Outliers: biological vs. technical
- Statistical test




# Choosing the appropriate statistical test

- The decision for a statistical test is based on the scientific question to be answered, the data structure and the study design.
- The question to be answered and the null hypothesis must be formulated before the data are recorded and the statistical test is selected.
- Select statistical test and the level of significance before the study begins to ensure that the study results do not influence the test selection.
- It must be decided whether the test should be one-tailed or two-tailed.
  - two-tailed means that no particular direction of expected difference is assumed.
  - one-tailed test should only be performed when there is clear evidence that the intervention should only act in one direction.




# Choosing the appropriate statistical test

group comparison with two categorical endpoints



group comparison of a continuous endpoint



# Summary

---



- RNA biology I
  - Introduction of RNA type and function
  - RNA quantification technology
    - Targeted
      - Northern blotting
      - *In situ* Hybridization
      - RT-qPCR
      - Reporter Assay
    - High-throughput
      - Microarray
      - RNA-seq
  - Experimental design principles
  - General workflow
- RNA biology II
  - Transcriptome profiling by RNA-seq
    - Experimental design
    - RNA quantification
    - Quality control and normalization
    - Outlier detection
    - Differentially expressed gene detection
    - Result interpretation





# Common Effect Size Indices

Index	Description <sup>b</sup>	Effect Size	Comments
Between groups			
Cohen's $d^a$	$d = M_1 - M_2 / s$ $M_1 - M_2$ is the difference between the group means ( $M$ ); $s$ is the standard deviation of either group	Small 0.2 Medium 0.5 Large 0.8 Very large 1.3	Can be used at planning stage to find the sample size required for sufficient power for your study
Odds ratio (OR)	$\frac{\text{Group 1 odds of outcome}}{\text{Group 2 odds of outcome}}$ If OR = 1, the odds of outcome are equally likely in both groups	Small 1.5 Medium 2 Large 3	For binary outcome variables Compares odds of outcome occurring from one intervention vs another
Relative risk or risk ratio (RR)	Ratio of probability of outcome in group 1 vs group 2; If RR = 1, the outcome is equally probable in both groups	Small 2 Medium 3 Large 4	Compares probabilities of outcome occurring from one intervention to another
Measures of association			
Pearson's $r$ correlation	Range, $-1$ to $1$	Small $\pm 0.2$ Medium $\pm 0.5$ Large $\pm 0.8$	Measures the degree of linear relationship between two quantitative variables
$r^2$ coefficient of determination	Range, $0$ to $1$ ; Usually expressed as percent	Small 0.04 Medium 0.25 Large 0.64	Proportion of variance in one variable explained by the other